Myriad Genetics, Inc. (MYGN)' HRD Test Predicts Response to Platinum Therapy in Triple-Negative Breast Cancer
12/10/2012 9:15:09 AM
SALT LAKE CITY, Dec. 7, 2012 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that a presentation entitled "Homologous recombination deficiency (HRD) score predicts pathologic response following neoadjuvant platinum-based therapy in triple-negative and BRCA1/2 mutation-associated breast cancer (BC)," was presented on Friday, December 7, 2012 at the CTRC-AACR San Antonio Breast Cancer Symposium in San Antonio, Texas. The study demonstrates that Myriad's HRD test strongly predicts which primary tumors will respond to platinum-based combination therapy in patients with triple-negative breast cancer.
comments powered by